Schubert & Co’s Corcept Therapeutics CORT Stock Holding History

Schubert & Co’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-6	Closed	-$130	–	365
2023 Q1	$130	Buy	6 +1	+20%	+$22	﹤0.01%	1584
2022 Q4	$102	Sell	5 -6	-55%	-$150	﹤0.01%	1578
2022 Q3	$0	Buy	11 +2	+22%	+$54	﹤0.01%	1409
2022 Q2	$0	Buy	9 +3	+50%	+$65	﹤0.01%	1472
2022 Q1	$0	Buy	6 +3	+100%	+$64	﹤0.01%	1116
2021 Q4	$0	Buy	+3	New	+$61	﹤0.01%	1052

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Schubert & Co's CORT Position: Q2 2023 in Review

Schubert & Co sold out of Corcept Therapeutics (CORT) in Q2 2023, closing a stake of 6 shares — an estimated $130 sold.

Schubert & Co first reported a position in CORT in Q4 2021 and held it in 6 quarters. The position peaked at $130 in Q1 2023. 224 funds tracked by Wall St. Rank hold CORT as of Q2 2023.

Schubert & Co reported no remaining Corcept Therapeutics position as of Q2 2023 after selling out during the quarter.
Schubert & Co sold 6 Corcept Therapeutics shares in Q2 2023, an estimated $130.
Schubert & Co first reported a position in Corcept Therapeutics in Q4 2021 and held it in 6 quarters.
Schubert & Co's Corcept Therapeutics position peaked at $130 in Q1 2023.
224 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.